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BACKGROUND: The disease caused by the severe acute respiratory RESULTS: Of 225 women, 23 (10.2%) had a positive test result for
syndrome coronavirus 2 was named coronavirus disease 2019 and
classified as a global public health emergency. The evidence related to the
impact of coronavirus disease 2019 on pregnancy is limited to the second
and third trimester of pregnancy, whereas data on the first trimester are
scant. Many viral infections can be harmful to the fetus during the first
trimester of pregnancy, and whether severe acute respiratory syndrome
coronavirus 2 is one of them is still unknown.
OBJECTIVE: With this study, we evaluated severe acute respiratory
syndrome coronavirus 2 infection as a risk factor for early pregnancy loss
in the first trimester of pregnancy. Furthermore, coronavirus disease 2019
course in the first trimester was assessed.
STUDY DESIGN: Between February 22 and May 21, 2020, we con-
ducted a case-control study at S. Anna Hospital, Turin, among pregnant
women in their first trimester, paired for last menstruation. The cumulative
incidence of coronavirus disease 2019 was compared between women
with spontaneous abortion (case group, n¼100) and those with ongoing
pregnancy (control group, n¼125). Current or past infection was deter-
mined by the detection of severe acute respiratory syndrome coronavirus 2
from nasopharyngeal swab and severe acute respiratory syndrome
coronavirus 2 immunoglobulin G and immunoglobulin M antibodies in a
blood sample. Patient demographics, coronavirus disease 2019erelated
symptoms, and the main risk factors for abortion were collected.Cite this article as: Cosma S, Carosso AR, Cusato J,
et al. Coronavirus disease 2019 and first trimester
spontaneous abortion: a case-control study of 225
pregnant patients. Am J Obstet Gynecol
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0002-9378/$36.00
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https://doi.org/10.1016/j.ajog.2020.10.005coronavirus disease 2019. There was no difference in the cumulative
incidence of coronavirus disease 2019 between the cases (11/100, 11%)
and the controls (12/125, 9.6%) (P¼.73). Logistic regression analysis
confirmed that coronavirus disease 2019 was not an independent pre-
dictor of early pregnancy loss (odds ratio, 1.28; confidence interval,
0.53e3.08). Coronavirus disease 2019erelated symptoms in the first
trimester were fever, anosmia, ageusia, cough, arthralgia, and diarrhea;
no cases of pneumonia or hospital admission owing to coronavirus disease
2019erelated symptoms were recorded. No difference in the incidence of
symptoms was noted between the 2 groups.
CONCLUSION: Severe acute respiratory syndrome coronavirus 2
infection during the first trimester of pregnancy does not seem to
predispose to early pregnancy loss; its cumulative incidence did not
differ between women with spontaneous abortion and women with
ongoing pregnancy. Coronavirus disease 2019 appears to have a
favorable maternal course at the beginning of pregnancy, consistent
with what has been observed during the second and third
trimesters.
Key words: abortion, coronavirus, COVID-19, fetus, first trimester,
miscarriage, pregnancy, pregnancy loss, preterm birth, SARS-CoV-2,
seroprevalence, severe acute respiratory syndrome, vertical transmissionIntroduction
TheWorld Health Organization named
the new severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2)
disease coronavirus disease 2019
(COVID-19) and declared it a
pandemic. Coronaviruses are envel-
oped, nonsegmented, positive-sense
RNA usually responsible for mild
illness such as the common cold in
adults and children.1 However, in thelast decade, coronaviruses have caused
2 important epidemics: severe acute
respiratory syndrome (SARS) and
Middle East respiratory syndrome
(MERS). COVID-19 was first reported
in Wuhan (China) in December 2019
followed by outbreaks across the world.2
The first cases of COVID-19 in Italy were
confirmed in January 2020, with a rapid
rise in the number of cases in northern
Italy starting in late February.
Despite the rapidly growing number of
cases worldwide, data on COVID-19
during pregnancy remain limited, being
derived mainly from small sample
studies.3e8 A systematic review of pub-
lished reports on coronaviruses (COVID-
19, SARS,MERS) reported higher rates of
preterm birth, preeclampsia, cesarean
delivery, and perinatal death.9 The lack ofAPRIL 2021 Ameridata on spontaneous abortion because of
COVID-19 during the first trimester
precludes extrapolation of conclusive ev-
idence for the effects of infection during
early pregnancy. The paucity of reliable
data has aroused concern in patients, and
the disinformation reported by the media
may lead pregnant women to embrace
dramatic choices such as voluntary
abortion.10
The wide range of clinical expression,
the high rate of asymptomatic forms,
and the poor accuracy of nasopharyngeal
swab testing and its limited availability
have been the main barriers to gaining
a real understanding of the prevalence
of the infection and its impact on
pregnancy. In this complex scenario,
the development of serologic tests
for the detection of SARS-CoV-2can Journal of Obstetrics & Gynecology 391.e1
AJOG at a Glance
Why was this study conducted?
Limited research exists on the outcomes of pregnant women with coronavirus
disease 2019 (COVID-19), with published research mostly related to women in
the second or third trimester. Evidence about maternal and obstetrical outcomes
of women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
during the first trimester or about the risk of early pregnancy loss is lacking.
Key findings
We report the largest series of patients with COVID-19 in the first trimester of
pregnancy to date. The study findings showed no significant difference in the
cumulative incidence of COVID-19 in women who experienced spontaneous
abortion (n¼100) than those with ongoing pregnancies (n¼125).
What does this add to what is known?
These findings may reassure women residing in COVID-19 epidemic areas who
are planning pregnancy and may provide obstetricians with a guide for precon-
ception counseling.
Original Research OBSTETRICS ajog.orgimmunoglobulin G (IgG) and immu-
noglobulin M (IgM) could be useful to
identify pregnant patients who were
infected during early pregnancy.
Although the quantity and quality of
data on test performance are still limited,
the level of accuracy has been reportedly
moderate to good, so that patients
infected by SARS-CoV-2 can be traced.11
This study aimed to evaluate the
impact of COVID-19 on first-trimester
pregnancy loss by comparing the cu-
mulative incidence of SARS-CoV-2
infection in a cohort of women who
experienced early spontaneous abortion
and that of women with ongoing preg-
nancy at 12 weeks of gestational age.
Furthermore, COVID-19 course in the
first trimester was evaluated.
Materials and Methods
Women who had been referred to our
hospital for pregnancy loss care during
the first 13 weeks of pregnancy between
February 22 and May 21, 2020 were
contacted and enrolled (case group). All
women who had access to our emer-
gency room or to the pregnancy loss
management service were contacted af-
ter being traced through our hospital’s
database. Women 12 weeks pregnant
who were admitted to our hospital for
fetal nuchal translucency (NT) between
April 16, 2020, and May 21, 2020, were
the control group.391.e2 American Journal of Obstetrics & GynecolAll pregnant women in Turin, Pied-
mont, are offered free of charge a
comprehensive first-trimester risk
assessment, performed at gestational age
of 11 to 13 weeks as part of the public
antenatal and obstetrical healthcare ser-
vice. The attendance rate is high. The
risk assessment includes a double test
(blood sample for pregnancy-associated
plasma protein A [PAPP-A] and free
beta human chorionic gonadotropin [b-
hCG]) and an ultrasound NT measure-
ment (combined screening test) or NT
measurement together with PAPP-A
dosage, and a further blood sample for
a-fetoprotein, free estriol, and b-hCG at
gestational age of 15 to 18 weeks (inte-
grated screening test).
The first reported case of COVID-19
infection in Piedmont was dated
February 22, 2020. To exclude the pos-
sibility of COVID-19 seroconversion
before pregnancy, only women with last
menstruation before that date were
considered eligible for inclusion
(Figure 1). This criterion allowed us to
define seropositivity in the case group as
a seroconversion that had occurred
during pregnancy.
Blood tests were performed for the
detection of IgG and IgM non-
neutralizing antibodies against SARS-
CoV-2 and reverse transcriptase-
polymerase chain reaction (RT-PCR)
assays on nasopharyngeal swabs.ogy APRIL 2021Patients with a positive result by at least 1
test were also tested for the determina-
tion of specific neutralizing antibodies.
Blood samples were centrifuged at 3000
rpm for 5 minutes to separate serum and
analyzed the same day of collection.
A rapid automated fluorescent lateral
flowCE-approved immunoassay (AFIAS
COVID-19, Boditech, Gang-won-do,
Republic of Korea) was used for quali-
tative and semiquantitative detection of
IgG and IgM nonneutralizing antibodies
against the spike (S) and nucleocapsid
(N) viral proteins; semiquantitative re-
sults are expressed as the cutoff index
(COI), in which a COI of >1.1 indicates
a positive result. Chemiluminescence
CE-approved immunoassay technology
was used for the semiquantitative
determination of anti-S1 and anti-S2
specific IgG neutralizing antibodies to
SARS-CoV-2 (Liaison SARS-CoV-2 S1/
S2 IgG, DiaSorin, Saluggia, Italy); the
antibody concentration is expressed as
arbitrary units (AU/mL) and grades the
results as positive when 15 AU/mL.
Viral RNA extraction from the swab was
performed on a MagNA Pure compact
instrument (Roche, Basel, Switzerland)
and analyzed using an RT-PCR assay
(CFX-96, Bio-Rad, Hercules, CA) with
the Liferiver Novel Coronavirus 2019-
nCov real-time RT-PCR kit protocol,
targeting genes N, E, and ORF1ab
(Liferiver Bio-Tech, San Diego, CA).
Sample size calculation was not
possible because the expected prevalence
of disease was unknown at the time of
population enrollment, and further
recruitment beyond May 21 would have
precluded the eligibility criterion for last
menstruation.
Demographics, COVID-19erelated
symptoms, and data on exposure to
possible risk factors for spontaneous
abortion were collected by interview.
The study was approved by the institu-
tional review board of the City of Health
and Science of Turin (reference number:
00171/2020). Written, informed consent
was obtained from all participants. The
results for quantitative variables are
expressed as the mean  standard devi-
ation (SD), and qualitative categorical
variables are expressed as frequency and
percentages. Comparison of quantitative
FIGURE 1
Inclusion criteria and time of serologic and molecular sampling in the case and the control group
Time range for last menstruation inclusion (blue line); first reported case of COVID-19 in Piedmont, Italy (dotted red line); time of sera and nasopharyngeal
swab sample collection (red line).
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COVID-19 outbreak cases in Piedmont Region: weekly case increase.
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ajog.org OBSTETRICS Original Researchvariables was performed using the t test
or Wilcoxon-Mann-Whitney test based
on normal or not distribution, respec-
tively. Qualitative variables were
compared using the chi-square test or
Fisher exact test, as appropriate. When
basic patient characteristics were present
as confounding factors, regression
analysis was performed to assess the
relationship between COVID-19 infec-
tion and spontaneous abortion. Results
are expressed as odds ratio (95% con-
fidence interval [CI]). Statistical ana-
lyses were performed using SAS
software version 9.4 for Windows (SAS
Institute, Cary, NC).
Results
A total of 225 women in the first
trimester of pregnancy attending our
institute were included in the study.
Overall, 100 women in the case group
and 125 women in the control group
were enrolled. The patient attendance
rate was 87% (100/115) and 88% (125/
142) in the case group and control
group, respectively. Table 1 reports the
patients’ characteristics at baseline;
except for age, there were no statistically
significant differences in demographics
or risk factors for abortion between the 2
groups.
Of the 225 women tested for antie
SARS-CoV-2 IgG and IgM antibodies,
23 were found to be seropositive or
their nasopharyngeal swab tested posi-
tive for COVID-19, yielding an overallcumulative incidence of 10.2% in the
first trimester. There was no significant
difference in the cumulative incidence of
COVID-19 between the case patients
(11/100, 11%) and the controls (12/125,
9.6%) (P¼.73).
The age variable was entered into lo-
gistic regression analysis to evaluate
COVID-19 infection in relation to con-
founders. There was no difference in the
odds of being infected with SARS-CoV-2
between the 2 groups, indicating that
COVID-19 infection was not an inde-
pendent predictor of early pregnancy
loss (1.282; 95% CI, 0.53e3.08).
Subgroup analysis of baseline charac-
teristics of COVID-19epositive and
COVID-19enegative patients with early
pregnancy loss (case group) showed no
statistically significant differences in de-
mographics or risk factors for sponta-
neous abortion between the 2 groups,
except for body mass index (BMI)
(26.45.2 vs 23.24.2; P¼.03).
In the case group, 5 of 11 (45.4%), 3 of
11 (27.2%), and 1 of 11 (9%) partici-
pants had a positive test result for SARS-
CoV-2 IgG, SARS-CoV-2 IgM, or both
SARS-CoV-2 IgG and IgM, respec-
tively; RT-PCR of the nasopharyngeal
swab was positive in 2 of 11 partici-
pants (18%) (Table 2). In the control
group, 7 of 12 (58.3%), 3 of 12 (25%),
and 2 of 12 (16.6%) had a positive test
result for SARS-CoV-2 IgG, SARS-
CoV-2 IgM, or both SARS-CoV-2 IgG
and IgM, respectively; RT-PCR of theAPRIL 2021 Amerinasopharyngeal swab was positive in 5
of 12 participants (41.7%) (Table 3).
No difference in positivity for IgG
neutralizing antibodies was found be-
tween the case (6/11, 54.5%) and the
control group (5/12, 41.7%) (P¼.53)
(Table 1). There was no statistically
significant difference between the 2
groups for average antibody titer, both
nonneutralizing (21.3 vs 18.3 COI;
P¼.42) and neutralizing antibodies
(39.9 vs 46.9 AU/mL; P¼.69).
Of the patients diagnosed as having
COVID-19, 12 reported previous
symptoms (12/23, 52.2%), including
fever (7/12, 58.3%), anosmia and ageusia
(5/12, 41.7%), cough (5/12, 41.7%),
arthralgia (4/12, 33.3%), and diarrhea
(1/12, 8.3%); no pneumonia or hospital
admission owing to COVID-19erelated
symptoms was recorded. No difference
in the incidence of symptoms was noted
between the case (4/11, 36.4%) and the
control group (8/12, 66.6%) (P¼.14).
Comment
Principal findings
With this case-control study, we evalu-
ated the impact of COVID-19 on early
pregnancy loss in a cohort of pregnant
women with SARS-CoV-2 infection
confirmed by antibody testing or RT-
PCR assay of nasopharyngeal swabs.
The results show that the risk of first-
trimester spontaneous abortion is not
affected by SARS-CoV-2 infection after
being adjusted for age. No severe casescan Journal of Obstetrics & Gynecology 391.e3
TABLE 1
Baseline characteristics, clinical findings, and COVID-19 cumulative
incidence in case and control groups
Clinical findings Case (n¼100) Control (n¼125) P value
Age, y 35.5 (4.7) 33.7 (4.7) .001
BMI before pregnancy,
kg/m2
25.5 (4.3) 22.6 (4.1) .11
Pregnancy 0 51 (51) 77 (61.6) .34
1 40 (40) 37 (29.6)
2 7 (7) 9 (7.2)
3 1 (1) 2 (1.6)
5 1 (1) 0 (0)
Previous abortion 0 66 (66) 94 (75.2) .11
1 27 (27) 21 (16.8)
2 6 (6) 7 (5.6)
3 0 (0) 3 (2.4)
6 1 (1) 0 (0)
ART therapy 7 (7) 12 (9.6) .48
Smoking history 22 (22) 16 (12.8) .06
Thyroid disease 10 (10) 11 (8.8) .75
Autoimmune diseases 8 (8) 4 (3.2) .11
Thrombophilia 5 (5) 5 (4) .75
Uncontrolled DM 0 0 >.99
Uterine abnormalities 8 (8) 9 (7.2) .82
COVID-19 disease 11 (11) 12 (9.6) .73
Values are presented as number (percentage) or mean (SD).
ART, assisted reproductive technique; BMI, body mass index; COVID-19, coronavirus disease 2019; DM, diabetes mellitus.
Cosma et al. Coronavirus disease 2019 and early pregnancy loss. Am J Obstet Gynecol 2021.
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COVID-19erelated symptoms were
recorded, both in women who had
ongoing pregnancies and in those with
early pregnancy loss.
Results in context
Despite the large and rapidly growing
number of cases worldwide, there are
limited data on COVID-19 in pregnancy,
mainly coming from case series and
small sample studies related to the sec-
ond and third trimesters of pregnancy.
Concern is mounting about the impact
of COVID-19 on pregnancy, possible
vertical transmission,12e15 and unfavor-
able obstetrical outcomes in particular.
Reproductive medicine societies advised
delaying the start of assisted reproduc-
tive treatments,16 and guidelines on the391.e4 American Journal of Obstetrics & Gynecolprevention and control of COVID-19
among pregnant women have been
issued.17e19
Currently, data on the impact of
coronaviruses on the first trimester of
pregnancy are limited. Four of the 7
patients who presented with SARS
coronavirus 1 (SARS-CoV-1) infection
during their first trimester had a spon-
taneous abortion, likely the result of the
hypoxia caused by SARS-CoV-1erelated
acute respiratory distress.20 Further-
more, 1 case of a woman with MERS
during the first trimester has been re-
ported. She was asymptomatic and went
on to have a term delivery.21 As for
SARS-CoV-2, a single pregnancy loss
during the second trimester of preg-
nancy in a woman with COVID-19 was
probably related to placental infection.22ogy APRIL 2021Another study reported the first visuali-
zation by electron microscopy of the
SARS-CoV-2 invading syncytiotropho-
blasts in the placental villi.23 This evi-
dence could suggest a potential impact of
SARS-CoV-2 on spontaneous abortion.
Clinical implications
Our study findings may reduce concerns
in patients during the first trimester of
pregnancy. In this cohort of women who
experienced a spontaneous abortion
during the first trimester, the serologic
prevalence of antibodies was similar to
that in women with ongoing pregnan-
cies. Furthermore, although viral infec-
tion at this stage could potentially affect
embryogenesis and organ development,
there is still no evidence for the intra-
uterine transmission of SARS-CoV-2.
Our findings may reassure women who
are planning a pregnancy in epidemic
areas and may represent a guide for ob-
stetricians during preconception
counseling.
The course of COVID-19 varies
widely: patients may remain asymp-
tomatic or develop mild to severe
symptoms leading to pneumonia, res-
piratory failure, and death.24 However,
in this cohort, few patients were symp-
tomatic and not more numerous in the
case group. Severe disease was never
observed. The lower incidence of severe
manifestations during the first trimester
could be explained by the minimal
alteration in respiratory dynamics dur-
ing this phase of pregnancy. Despite
these reassuring data, pregnancies in
women with COVID-19 can still have an
unfavorable obstetrical outcome: in-
flammatory involvement of the
placenta25 can be associated with pre-
term delivery.26 Obstetricians should
discuss that although the first trimester
seems not to expose the fetus to severe
risks, pregnancy may still be complicated
in the following weeks of gestation.
Research implications
Serologic tests, in conjunction with
SARS-CoV-2 RT-PCR assays, may offer a
more feasible opportunity to identify
both active and past infections and
evaluate the real spread of SARS-CoV-2
to the point that some governments
TABLE 2
Antibody levels and SARS-CoV-2 detection in sera and NS samples from patients with abortion
Diagnostic test Positive result
Patient
1 2 3 4 5 6 7 8 9 10 11
Anti-NP IgM COI>1.1 <1.1 2.11 <1.1 1.9 <1.1 <1.1 <1.1 <1.1 2.6 <1.1 2.9
Anti-NP IgG COI>1.1 <1.1 18.9 <1.1 <1.1 19.4 <1.1 14.4 32.4 <1.1 21.7 <1.1
Anti-RBD IgG 15 AU/mL <15 19.5 <15 <15 29.9 49.3 17.3 41 <15 82.9 <15
NS pos neg pos neg neg neg neg neg neg neg neg
COI, cutoff index; IgG, immunoglobulin G; IgM, immunoglobulin M; neg, negative; NP, nucleoprotein; NS, nasopharyngeal swab; pos, positive; RBD, receptor-binding domain; SARS-CoV-2, severe
acute respiratory syndrome coronavirus 2.
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population tracking.27 Determination
of seroconversion in pregnant women
could answer some concerns about un-
favorable pregnancy outcomes, which
are not otherwise resolvable. The non-
negligible prevalence of infection in
asymptomatic pregnant women re-
ported in our cohort and elsewhere8,28
makes universal screening of all preg-
nant patients seem desirable. Long-term
follow-up of ongoing pregnancies will
respond to other doubts about the
impact of COVID-19 in pregnant
patients.
Strengths and limitations
One of the strengths of this study is the
enrollment of women with serologically
confirmed COVID-19 by means of 2
different serologic assays; the combined
results of RT-PCR and nasopharyngeal
swab samples is another major strength
of the study. The high attendance rate to
the study protocol limited confoundingTABLE 3
Antibody levels and SARS-CoV-2 detec
Diagnostic test Positive result
Patient
1 2
Anti-NP IgM COI>1.1 <1.1 <
Anti-NP IgG COI>1.1 19.3 1
Anti-RBD IgG 15 AU/mL <15
NS neg p
COI, cutoff index; IgG, immunoglobulin G; IgM, immunoglobulin M
acute respiratory syndrome coronavirus 2.
Cosma et al. Coronavirus disease 2019 and early pregnancyfactors such as population selection
bias. Antibodies to COVID-19 were
detected in about 1 of 10 pregnant
patients in the cohort; however, this
finding should be carefully interpreted,
as it cannot be generalized given that
the cohort was derived from a single
center located in a region with a high
incidence of COVID-19.
Although the number of COVID-
19epositive patients in the case group is
low, except for BMI, the group does not
differ in baseline characteristics from the
COVID-19enegative patients with early
pregnancy loss. This suggests that the
study conclusions may be extended to
larger samples. Overweight among
COVID-19 patients has been reported in
other series of nonpregnant patients and
is being increasingly described as an
underappreciated risk factor for
COVID-19.29A major limitation of the
study is that we were unable to accurately
backdate the time of infection in women
with spontaneous abortion. In thetion in sera and NS samples from pregna
3 4 5 6 7
1.1 <1.1 2.1 1.6 1.2 1.2
9.3 15.6 <1.1 <1.1 21 <1.1
<15 <15 <15 <15 52.7 <15
os neg neg neg pos neg
; neg, negative; NP, nucleoprotein; NS, nasopharyngeal swab; pos, p
loss. Am J Obstet Gynecol 2021.
APRIL 2021 Ameriabsence of an IgG avidity test, we eval-
uated the time elapsed between the
abortion and the blood test for antibody
detection. The profile of antibodies
against SARS-CoV-2 in this cohort was
comparable with previous findings.
Seroconversion of IgG or IgM within 20
days after symptom onset has recently
been reported.30 The median day of
seroconversion for both IgG and IgM
was 13 days with a synchronous or a
discordant pattern. In light of this evi-
dence, seroconversion during pregnancy
could be excluded (or be controversial)
only in 1 patient (no. 4, Figure 2) in the
case group. The detection of IgM anti-
bodies at 66 days after abortion does not
preclude that seroconversion might have
occurred after the loss of pregnancy. In
view of future research addressing the
issue on the relationship between
COVID-19 and spontaneous abortion, it
will be difficult for researchers to pre-
cisely define the timing of infection and
the effective seroconversion duringnt patients
8 9 10 11 12
<1.1 1.2 <1.1 <1.1 <1.1
21.5 23.2 21.9 2.45 20.7
21.1 103 30.5 <15 27.5
pos neg pos neg pos
ositive; RBD, receptor-binding domain; SARS-CoV-2, severe
can Journal of Obstetrics & Gynecology 391.e5
FIGURE 2
Time elapsed between spontaneous abortion care, diagnostic testing and seromolecular profiles
Last menstruation (black arrow); hospital care for early pregnancy loss (black vertical line); first reported case of COVID-19 in Piedmont (dotted black line);
time elapsed between the spontaneous abortion and diagnostic testing (rectangular green box); pregnancy (rectangular violet box); serological and/or
molecular sampling (red line); reported COVID-19erelated symptoms (x); days elapsed between the spontaneous abortion and diagnostic testing
(asterisk).
0 1k 2k 3k 4k
COVID-19 outbreak cases in Piedmont Region: weekly case increase.
GA, gestational age; IgG, immunoglobulin G; IgM, immunoglobulin M; neg, negative; NS, nasopharyngeal swab.
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with the beginning of the study at
pandemic outbreak, allowed us to fairly
overcome this issue.
Another limitation is that patients with
very early pregnancy loss may not have
been enrolled in our study because they
did not require obstetrical care, which is
performed before the patient has her first
obstetrical visit. We believe, however, that
there is no reason to think that within this
small patient group the cumulative inci-
dence of COVID-19 would have been so
high as to question our results. It is
difficult to hypothesize that preclinical
abortions could be caused by SARS-CoV-
2 in a stage when pregnancy loss is much
more likely to occur because of chromo-
somal defects in the embryo rather than
because of virus-induced detrimental391.e6 American Journal of Obstetrics & Gynecoleffects at the maternal-fetal
interface.31e33 Recent evidence shows
that SARS-COV-2 binds to angiotensin-
converting enzyme 2 (ACE2) receptors
and the cellular transmembrane serine
protease 2 (TMPRSS2) to facilitate the
fusion of viral and cellular target mem-
branes. Because coexpression of ACE2
and TMPRSS2 at such an early stage of
pregnancy is negligible,34 we believe our
groups are reasonably representative and
our analysis realistic.
Conclusions
Our study provides reassuring findings
for women who intend to become preg-
nant during the SARS-CoV-2 pandemic
or who became infected during their first
trimester of pregnancy. COVID-19 ap-
pears to have a favorable maternal courseogy APRIL 2021at the beginning of pregnancy, consistent
with what has been observed during the
third trimester when the clinical charac-
teristics of COVID-19epositive pregnant
women were similar to those found in
women from the general population.35
More importantly, no significant differ-
ence in the early pregnancy loss rate was
observed. n
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